CollMED Laboratories

Collagen Medical (CollMED) is a clinical-stage biotechnology company focused on developing targeted imaging agents for the detection and monitoring of fibrotic diseases. The company's lead candidate, CM-101, is a collagen-targeted MRI contrast agent designed to quantify the extent of fibrosis in organs such as the liver, lungs, and heart. By specifically binding to type I collagen, which is overexpressed during active fibrogenesis, CollMED's technology aims to provide a non-invasive alternative to traditional biopsies. The company's pipeline addresses significant unmet needs in indications like nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis.